ATAI
HealthcareAtai Beckley N.V · Medical - Pharmaceuticals · $2B
What is Atai Beckley N.V?
Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. Headquartered in Amstelveen, Netherlands, the company is working to bring novel therapies through clinical development.
The company pursues drug development programs targeting mental health conditions, an area with significant unmet medical need. As a clinical-stage company, Atai Beckley does not yet generate product revenue — its value is tied to the progress of its pipeline candidates through clinical trials. The business model centers on advancing compounds toward regulatory approval, with the goal of eventually commercializing treatments or partnering with larger pharmaceutical companies.
Atai Beckley NV was founded in 2018 and is headquartered in Amstelveen, Netherlands.
- Clinical-stage mental health drug development programs
- Pipeline targeting psychiatric and neurological disorders
- Research-driven approach to treatment-resistant conditions
- Potential partnership and licensing opportunities with larger pharma
Is ATAI a Good Stock to Buy?
UQS Score rates ATAI as Poor overall, reflecting the significant challenges typical of early-stage biopharmaceutical companies.
The Risk pillar stands out as the relative bright spot in ATAI's profile, suggesting the company maintains a degree of financial resilience — not uncommon for clinical-stage firms that have raised capital ahead of commercialization. Growth is rated Neutral, indicating the pipeline trajectory is neither a clear catalyst nor a drag at this stage.
Both the Quality and Moat pillars are rated Weak, which reflects the absence of commercial revenue and durable competitive advantages typical of pre-approval biopharma. Valuation is rated Elevated, meaning the current market price may not offer a margin of safety given the pipeline risks.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ATAI pay dividends?
No — Atai Beckley N.V does not currently pay a dividend.
ATAI does not pay a dividend, which is standard for clinical-stage biopharmaceutical companies. Available capital is directed toward funding research, clinical trials, and pipeline advancement rather than shareholder distributions. Investors in this space typically seek returns through potential pipeline milestones and eventual commercialization rather than income.
When does ATAI report earnings?
Atai Beckley NV reports financial results on a quarterly cadence, consistent with US-listed equities.
As a pre-revenue clinical-stage company, quarterly reports focus primarily on cash runway, operating expenses, and pipeline progress rather than traditional revenue or profit metrics. Key items to watch include trial updates and capital position disclosures.
For the most recent quarter's results and pipeline updates, visit Atai Beckley NV's investor relations page directly.
ATAI Price History
-73.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Atai Beckley N.V?
Based on Atai Beckley N.V's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
ATAI Long-term Outlook
The fundamental outlook for ATAI is shaped by its clinical-stage status and the binary nature of drug development. With Growth rated Neutral, the pipeline offers potential upside if candidates advance, but the Weak Quality and Moat ratings reflect the absence of near-term revenue visibility. The Elevated Valuation rating suggests the market has priced in optimism that may not yet be supported by clinical data, making the risk-reward profile highly dependent on trial outcomes.
Growth drivers
- Advancement of pipeline candidates through clinical trial milestones
- Growing demand for novel mental health treatments globally
- Potential partnership or licensing deals with established pharmaceutical companies
Key risks
- Clinical trial failure or delays could significantly impair value
- Elevated valuation leaves limited margin of safety if pipeline disappoints
- Ongoing cash consumption with no commercial revenue to offset costs
ATAI vs Peers
ATAI operates in a competitive clinical-stage landscape alongside other development-focused companies pursuing niche therapeutic areas.
Cullinan focuses on oncology pipeline development, distinguishing it from ATAI's mental health therapeutic focus.
Galecto targets fibrosis and oncology indications, representing a different disease area than ATAI's psychiatric pipeline.
High Tide operates in cannabis retail and accessories, offering a distinct business model compared to ATAI's pure clinical-stage drug development approach.
Frequently Asked Questions
What does Atai Beckley NV do?
Atai Beckley NV is a clinical-stage biopharmaceutical company developing treatments for mental health disorders. The company advances drug candidates through clinical trials with the goal of addressing significant unmet needs in psychiatry and neurology. It does not yet generate commercial product revenue.
Does ATAI pay dividends?
No, ATAI does not pay a dividend. Clinical-stage biopharmaceutical companies typically reinvest all available capital into research and pipeline development. Investors in ATAI are generally seeking potential returns from pipeline progress rather than income distributions.
When does ATAI report earnings?
Atai Beckley NV reports on a quarterly cadence, as is standard for US-listed companies. Because it is pre-revenue, reports focus on pipeline updates and cash position rather than traditional earnings metrics. Check the company's investor relations page for the latest schedule.
Is ATAI a good stock to buy?
UQS Score rates ATAI as Poor overall, driven by Weak Quality and Moat ratings alongside an Elevated Valuation. The Risk pillar provides some relative comfort, but the overall profile reflects the high uncertainty inherent in clinical-stage drug development. The complete pillar breakdown is available to UQS Pro members.
Is ATAI overvalued?
The UQS Valuation pillar for ATAI is rated Elevated, suggesting the current market price may not offer a meaningful margin of safety relative to the company's clinical-stage profile and lack of commercial revenue. This is a common dynamic for early-stage biopharma stocks where market expectations run ahead of pipeline progress.
How does ATAI compare to its competitors?
ATAI competes in a broader universe of small-cap clinical-stage companies, including Cullinan Therapeutics and Galecto, though each pursues different therapeutic areas. Unlike some peers, ATAI's focus is specifically on mental health, a space with high unmet need but also high development risk. Full UQS comparisons are available to Pro members.
What is ATAI's market cap bracket?
ATAI is classified as a small-cap stock. This places it in a segment of the market characterized by higher volatility and liquidity risk compared to large- or mega-cap peers, though small-cap clinical-stage companies can offer significant upside if pipeline milestones are achieved.
Who founded Atai Beckley NV?
Atai Beckley NV was founded in June 2018 by Christian Angermayer, Florian Brand, Srinivas Rao, and Lars Christian Wilde. The company is headquartered in Amstelveen, Netherlands.
Is ATAI a long-term quality investment?
From a long-term quality perspective, ATAI's UQS profile — rated Poor overall with Weak Quality and Moat pillars — indicates the company has not yet established the durable fundamentals associated with high-quality long-term holdings. Pipeline success could change this trajectory, but current indicators reflect early-stage risk. View the full analysis with a Pro account.
What is the main competitive advantage of Atai Beckley NV?
At this stage, ATAI's potential advantage lies in its focus on mental health — a therapeutic area with large unmet need and limited approved options. However, the UQS Moat pillar is rated Weak, reflecting that clinical-stage companies have not yet built the durable competitive advantages seen in commercial-stage peers.
What sector does ATAI belong to?
ATAI operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals. This segment is characterized by binary risk tied to clinical trial outcomes, regulatory decisions, and capital market conditions. Investors can explore other [Healthcare stocks scored by UQS](/sector/healthcare) for broader context.
Unlock Full ATAI Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact scores across all five UQS pillars
- ✓Access complete financial metrics and trend data
- ✓Compare ATAI against clinical-stage peers
- ✓See detailed Quality and Moat breakdowns
- ✓Track valuation changes over time
- ✓Get the full analyst-grade view in one place
Pro Analysis
ATAI — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 14, 2026 | 23.6 | 0.4 | 14.0 | 43.8 | 74.7 | 0.0 | +1.0 |
| May 11, 2026 | 22.6 | 0.4 | 14.0 | 43.8 | 68.3 | 0.0 | +0.1 |
| May 10, 2026 | 22.5 | 0.0 | 14.0 | 43.8 | 68.3 | 0.0 | -0.1 |
| Apr 2, 2026 | 22.6 | 0.4 | 14.0 | 43.8 | 68.3 | 0.0 | — |
ATAI — Pillar Breakdown
Quality
— 0.4/100 (25%)Atai Beckley N.V currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 43.8/100 (20%)Atai Beckley N.V shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 74.7/100 (15%)Atai Beckley N.V maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Atai Beckley N.V appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 14/100 (25%)Atai Beckley N.V operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ATAI.
Score Composition
Financial Data
More Stock Analysis
How is the ATAI UQS Score Calculated?
The UQS (Unified Quality Score) for Atai Beckley N.V is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Atai Beckley N.V's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Atai Beckley N.V is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.